Deciphering the role of heterozygous mutations in genes associated with parkinsonism

Lancet Neurology

Volumn 6, Issue 7, 2007, Pages 652-662

  Klein, Christine ^a,b   Lohmann Hedrich, Katja ^a   Rogaeva, Ekaterina ^c   Schlossmacher, Michael G ^d   Lang, Anthony E ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; LEUCINE RICH REPEAT KINASE 2; PARKIN; PTEN INDUCED PUTATIVE KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; INHERITANCE; LRRK2 GENE; ONSET AGE; PARK2 GENE; PARKINSON DISEASE; PARKINSONISM; PINK1 GENE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 34250372427     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70174-6     Document Type: Note

References (125)

1. Klein C., and Schlossmacher M. The genetics of Parkinson disease. Nat Clinl Pract Neurol 2 (2006) 136-146
2. Lucking C., Durr A., Bonifati V., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342 (2000) 1560-1567
3. Lesage S., Durr A., Tazir M., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354 (2006) 422-423
4. Ozelius L., Senthil G., Saunders-Pullman R., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354 (2006) 424-425
5. Polymeropoulos M., Lavedan C., Leroy E., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
6. Kitada T., Asakawa S., Hattori N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
7. Valente E., Abou-Sleiman P., Caputo V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
8. Bonifati V., Rizzu P., Squitieri F., et al. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24 (2003) 159-160
9. Zimprich A., Biskup S., Leitner P., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
10. Paisan-Ruiz C., Jain S., Evans E., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
11. Ramirez A., Heimbach A., Grundemann J., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 (2006) 1184-1191
12. Spillantini M., Schmidt M., Lee V., Trojanowski J., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
13. Galpern W., and Lang A. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59 (2006) 449-458
14. Berg D., Niwar M., Maass S., et al. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord 20 (2005) 1191-1194
15. Tan E., Tan C., Zhao Y., et al. Genetic analysis of DJ-1 in a cohort Parkinson's disease patients of different ethnicity. Neurosci Lett 367 (2004) 109-112
16. Klein C., Djarmati A., Hedrich K., et al. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet 13 (2005) 1086-1093
17. Forman M., Lee V., and Trojanowski J. Nosology of Parkinson's disease: looking for the way out of a quagmire. Neuron 47 (2005) 479-482
18. Abeliovich A., and Beal M. Parkinsonism genes: culprits and clues. J Neurochem 99 (2006) 1062-1072
19. Kay D., Kramer P., Higgins D., Zabetian C., and Payami H. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord 20 (2005) 1077-1078
20. Carmine Belin A., Westerlund M., Sydow O., et al. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord 21 (2006) 1731-1734
21. Hatano Y., Li Y., Sato K., et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 56 (2004) 424-427
22. Goldwurm S., Di Fonzo A., Simons E., et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 42 (2005) e65
23. Hedrich K., Hagenah J., Djarmati A., et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?. Arch Neurol 63 (2006) 833-838
24. Mata I., Kachergus J., Taylor J., et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6 (2005) 171-177
25. Mamah C., Lesnick T., Lincoln S., et al. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. Ann Neurol 57 (2005) 439-443
26. Maraganore D., Lesnick T., Elbaz A., et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 55 (2004) 512-521
27. Tan E., Zhao Y., Skipper L., et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 120 (2006) 857-863
28. McInerney-Leo A., Hadley D., Gwinn-Hardy K., and Hardy J. Genetic testing in Parkinson's disease. Mov Disord 20 (2005) 1-10
29. Lohmann E., Periquet M., Bonifati V., et al. How much phenotypic variation can be attributed to parkin genotype?. Ann Neurol 54 (2003) 176-185
30. Nichols W., Pankratz N., Hernandez D., et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365 (2005) 410-412
31. Zabetian C., Samii A., Mosley A., et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 (2005) 741-744
32. Kay D., Zabetian C., Factor S., et al. Parkinson's disease and LRRK2: frequency of a common mutation in US movement disorder clinics. Mov Disord 21 (2006) 519-523
33. Ishihara L., Warren L., Gibson R., et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol 63 (2006) 1250-1254
34. Hedrich K., Winkler S., Hagenah J., et al. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov Disord 21 (2006) 1506-1510
35. Civitelli D., Tarantino P., Nicoletti G., et al. LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson's disease. Clin Genet 71 (2007) 367-370
36. Ferreira J., Guedes L., Rosa M., et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Mov Disord (2007). published online April 27. DOI:10.1002/mds.21525
37. Funayama M., Hasegawa K., Ohta E., et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57 (2005) 918-921
38. Farrer M., Stone J., Mata I., et al. LRRK2 mutations in Parkinson disease. Neurology 65 (2005) 738-740
39. Paisan-Ruiz C., Lang A., Kawarai T., et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65 (2005) 696-700
40. Kachergus J., Mata I., Hulihan M., et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76 (2005) 672-680
41. Lesage S., Ibanez P., Lohmann E., et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 58 (2005) 784-787
42. Berg D., Schweitzer K., Leitner P., et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 128 (2005) 3000-3011
43. Di Fonzo A., Tassorelli C., De Mari M., et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14 (2006) 322-331
44. Lesage S., Leutenegger A., Ibanez P., et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77 (2005) 330-332
45. Gloeckner C., Kinkl N., Schumacher A., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15 (2006) 223-232
46. Smith W., Pei Z., Jiang H., Dawson V., Dawson T., and Ross C. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9 (2006) 1231-1233
47. West A., Moore D., Biskup S., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102 (2005) 16842-16847
48. Smith W., Pei Z., Jiang H., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 102 (2005) 18676-18681
49. Greggio E., Jain S., Kingsbury A., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23 (2006) 329-341
50. West A., Moore D., Choi C., et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16 (2007) 223-232
51. Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O., and Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 59 (2006) 714-719
52. Simon-Sanchez J., Herranz-Perez V., Olucha-Bordonau F., and Perez-Tur J. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur J Neurosci 23 (2006) 659-666
53. Giasson B., Covy J., Bonini N., et al. Biochemical and pathological characterization of Lrrk2. Ann Neurol 59 (2006) 315-322
54. Clark L., Wang Y., Karlins E., et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67 (2006) 1786-1791
55. Gaig C., Ezquerra M., Marti M., Munoz E., Valldeoriola F., and Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 63 (2006) 377-382
56. Adams J., van Netten H., Schulzer M., et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128 (2005) 2777-2785
57. Wszolek Z., Pfeiffer R., Tsuboi Y., et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62 (2004) 1619-1622
58. Rajput A., Dickson D., Robinson C., et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67 (2006) 1506-1508
59. Deng H., Le W., Hunter C., et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 63 (2006) 273-277
60. Tassin J., Durr A., Bonnet A., et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?. Brain 123 (2000) 1112-1121
61. Pramstaller P., Schlossmacher M., Jacques T., et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 58 (2005) 411-422
62. Hedrich K., Eskelson C., Wilmot B., et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 19 (2004) 1146-1157
63. Hedrich K., Kann M., Lanthaler A., et al. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 10 (2001) 1649-1656
64. Shimura H., Hattori N., Kubo S., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000) 302-305
65. Hampe C., Ardila-Osorio H., Fournier M., Brice A., and Corti O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet 15 (2006) 2059-2075
66. Zhang Y., Gao J., Chung K., Huang H., Dawson V., and Dawson T. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 97 (2000) 13354-13359
67. Petrucelli L., O'Farrell C., Lockhart P., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36 (2002) 1007-1019
68. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 (2003) 911-924
69. Feany M., and Pallanck L. Parkin: a multipurpose neuroprotective agent?. Neuron 38 (2003) 13-16
70. Palacino J., Sagi D., Goldberg M., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279 (2004) 18614-18622
71. Pesah Y., Pham T., Burgess H., et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131 (2004) 2183-2194
72. Periquet M., Corti O., Jacquier S., and Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 95 (2005) 1259-1276
73. Cookson M., Lockhart P., McLendon C., O'Farrell C., Schlossmacher M., and Farrer M. RING finger 1 mutations in Parkin produce altered localization of the protein. Hum Mol Genet 12 (2003) 2957-2965
74. Henn I., Gostner J., Lackner P., Tatzelt J., and Winklhofer K. Pathogenic mutations inactivate parkin by distinct mechanisms. J Neurochem 92 (2005) 114-122
75. Schlossmacher M., and Shimura H. Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin. Methods Mol Biol 301 (2005) 351-369
76. Healy D., Abou-Sleiman P., Gibson J., et al. PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology 63 (2004) 1486-1488
77. Rogaeva E., Johnson J., Lang A., et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 61 (2004) 1898-1904
78. Li Y., Tomiyama H., Sato K., et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology 64 (2005) 1955-1957
79. Bonifati V., Rohe C., Breedveld G., et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65 (2005) 87-95
80. Tan E., Yew K., Chua E., et al. PINK1 mutations in sporadic early-onset Parkinson's disease. Mov Disord 21 (2006) 789-793
81. Silvestri L., Caputo V., Bellacchio E., et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14 (2005) 3477-3492
82. Petit A., Kawarai T., Paitel E., et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 280 (2005) 34025-34032
83. Beilina A., Van Der Brug M., Ahmad R., et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci USA 102 (2005) 5703-5708
84. Sim C., Lio D., Mok S., et al. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 15 (2006) 3251-3262
85. Clark I., Dodson M., Jiang C., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 (2006) 1162-1166
86. Park J., Lee S., Lee S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 (2006) 1157-1161
87. Hedrich K., Djarmati A., Schafer N., et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62 (2004) 389-394
88. Hedrich K., Marder K., Harris J., et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 58 (2002) 1239-1246
89. West A., Periquet M., Lincoln S., et al. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet 114 (2002) 584-591
90. Valente E., Salvi S., Ialongo T., et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 56 (2004) 336-341
91. Abou-Sleiman P., Muqit M., McDonald N., et al. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann Neurol 60 (2006) 414-419
92. Klein C. Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 63 (2006) 328-334
93. Sun M., Latourelle J., Wooten G., et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 63 (2006) 826-832
94. Munoz E., Tolosa E., Pastor P., et al. Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism. J Neurol Neurosurg Psychiatry 73 (2002) 582-584
95. Adel S., Djarmati A., Kabakci K., et al. Co-occurrence of restless legs syndrome and Parkin mutations in two families. Mov Disord 21 (2006) 258-263
96. Lincoln S., Maraganore D., Lesnick T., et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov Disord 18 (2003) 1306-1311
97. Kay D., Moran D., Moses L., et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 61 (2007) 47-54
98. Clark L., Afridi S., Karlins E., et al. Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol 63 (2006) 548-552
99. Kann M., Jacobs H., Mohrmann K., et al. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol 51 (2002) 621-625
100. Farrer M., Chan P., Chen R., et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50 (2001) 293-300
101. Khan N., Horta W., Eunson L., et al. Parkin disease in a Brazilian kindred: manifesting heterozygotes and clinical follow-up over 10 years. Mov Disord 20 (2005) 479-484
102. Criscuolo C., Volpe G., De Rosa A., et al. PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. Mov Disord 21 (2006) 1265-1267
103. Hiller A., Hagenah J., Djarmati A., et al. Phenotypic spectrum of PINK1-associated parkinsonism in 15 mutation carriers from 1 family. Mov Disord 22 (2007) 145-147
104. Munhoz R., Sa D., Rogaeva E., et al. Clinical findings in a large family with a parkin ex3delta40 mutation. Arch Neurol 61 (2004) 701-704
105. Chien H., Rohe C., Costa M., et al. Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil. Neurogenetics 7 (2006) 13-19
106. Chishti M., Bohlaga S., Ahmed M., et al. A T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset parkinsonism. Arch Neurol 63 (2006) 1483-1485
107. Foroud T., Uniacke S., Liu L., et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60 (2003) 796-801
108. Gandhi S., Muqit M., Stanyer L., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 (2006) 1720-1730
109. Tang B., Xiong H., Sun P., et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15 (2006) 1816-1825
110. Dalkilic I., and Kunkel L. Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev 13 (2003) 231-238
111. Baker M., Mackenzie I., Pickering-Brown S., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442 (2006) 916-919
112. Hwu W., Chiou Y., Lai S., and Lee Y. Dopa-responsive dystonia is induced by a dominant-negative mechanism. Ann Neurol 48 (2000) 609-613
113. Son J., Kawamata H., Yoo M., et al. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. J Neurochem 94 (2005) 1040-1053
114. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 83 (2004) 6-15
115. Hilker R., Klein C., Ghaemi M., et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 49 (2001) 367-376
116. Khan N., Valente E., Bentivoglio A., et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 52 (2002) 849-853
117. Hilker R., Klein C., Hedrich K., et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett 323 (2002) 50-54
118. Walter U., Klein C., Hilker R., Benecke R., Pramstaller P., and Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 19 (2004) 1445-1449
119. Hagenah JM, Konig IR, Becker B, et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol (in press).
120. Binkofski F, Reetz K, Gaser C, et al. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology (in press).
121. Buhmann C., Binkofski F., Klein C., et al. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 128 (2005) 2281-2290
122. Ohsawa Y., Kurokawa K., Sonoo M., et al. Reduced amplitude of the sural nerve sensory action potential in PARK2 patients. Neurology 65 (2005) 459-462
123. Helmchen C., Schwekendiek A., Pramstaller P., Hedrich K., Klein C., and Rambold H. Blink amplitude but not saccadic hypometria indicates carriers of Parkin mutations. J Neurol 253 (2006) 1071-1075
124. Pearson H. Genetics: what is a gene?. Nature 441 (2006) 398-401
125. Scherzer C., Eklund A., Morse L., et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 104 (2007) 955-960